去纤苷治疗SARS-CoV-2相关ARDS的安全性初探
这项前瞻性、开放标签、单中心安全性试验纳入12例SARS-CoV-2相关ARDS患者,给予去纤苷6.25 mg/kg/次静脉注射每6小时一次、计划7天。治疗期间未发生出血或血栓并发症,未见归因于去纤苷的其他不良事件;第30天全因死亡率为17%(95%CI,0%-35%)。
要点
- 去纤苷治疗期间未观察到出血或血栓并发症,耐受性良好。
- 基线PaO2/FiO2≥125 mm Hg者全部存活,<125 mm Hg的3例均死亡。
- 9例(75%)在开始去纤苷后64至174天仍存活。
核心结论
- 去纤苷用于SARS-CoV-2相关ARDS的管理安全且可耐受,在既往死亡率较高的患者人群中显示出有希望的结果。
研究设计与样本
- 前瞻性、开放标签、单中心安全性试验。
- 纳入18岁及以上、有ARDS临床和影像学征象、无活动性出血、血清D-二聚体超过正常上限两倍、SARS-CoV-2 PCR阳性的患者。
- 共治疗12例患者,中位年龄63岁;10例接受机械通气,6例入组时接受血管升压药支持。
主要发现
- 入组时中位D-二聚体为3.25 μg/ml(范围,1.33-12.3)。
- 去纤苷(6.25 mg/kg/次,静脉注射,每6小时一次)计划疗程7天,中位治疗持续时间7天。
- 治疗期间未发生出血或血栓并发症,未记录到归因于去纤苷的其他不良事件。
- 4例患者达到第7天肺部反应参数,这4例均在去纤苷治疗最初72小时内血清D-二聚体下降。
- 3例患者分别在入组后11、17、34天死于进展性肺部疾病;9例(75%)在开始去纤苷后64至174天仍存活;第30天全因死亡率为17%(95%CI,0%-35%)。
关键数值与推荐
- 去纤苷剂量为6.25 mg/kg/次,静脉注射,每6小时一次,计划7天疗程。
- 入组要求血清D-二聚体超过正常上限两倍。
- 第30天全因死亡率为17%(95%CI,0%-35%)。
临床怎么用
- 对符合入选标准(D-二聚体>2倍正常上限、无活动性出血)的SARS-CoV-2相关ARDS患者,可考虑去纤苷治疗并每日监测D-二聚体与呼吸功能。
- 治疗期间需关注出血与血栓事件;基线PaO2/FiO2<125 mm Hg者预后差。
局限性
- 单中心、开放标签、样本量小(12例),无对照组,安全性结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SARS-CoV-2-related ARDS is associated with endothelial dysfunction and profound dysregulation of the thrombotic-fibrinolytic pathway. Defibrotide is a polyanionic compound with fibrinolytic, antithrombotic, and antiinflammatory properties. RESEARCH QUESTION: What is the safety and tolerability of defibrotide in patients with severe SARS-CoV-2 infections? STUDY DESIGN AND METHODS: We report a prospective, open-label, single-center safety trial of defibrotide for the management of SARS-CoV-2-related ARDS. Eligible participants were 18 years of age or older with clinical and radiographic signs of ARDS, no signs of active bleeding, a serum D-dimer of more than twice upper limit of normal, and positive polymerase chain reaction-based results for SARS-CoV-2. Defibrotide (6.25 mg/kg/dose IV q6h) was administered for a planned 7-day course, with serum D-dimer levels and respiratory function monitored daily during therapy. RESULTS: Twelve patients (median age, 63 years) were treated, with 10 patients receiving mechanical ventilation and 6 receiving vasopressor support at study entry. The median D-dimer was 3.25 μg/ml (range, 1.33-12.3) at study entry. The median duration of therapy was 7 days. No hemorrhagic or thrombotic complications occurred during therapy. No other adverse events attributable to defibrotide were noted. Four patients met the day 7 pulmonary response parameter, all four showing a decrease in serum D-dimer levels within the initial 72 h of defibrotide therapy. Three patients died of progressive pulmonary disease 11, 17, and 34 days after study entry. Nine patients (75%) remain alive 64 to 174 days after initiation of defibrotide. Day 30 all-cause mortality was 17% (95% CI, 0%-35%). All patients with a baseline Pao2 to Fio2 ratio of ≥ 125 mm Hg survived, whereas the three patients with a baseline Pao2 to Fio2 ratio of < 125 mm Hg died. INTERPRETATION: The use of defibrotide for management of SARS-CoV-2-related ARDS proved safe and tolerable. No hemorrhagic or thrombotic complications were reported during therapy, with promising outcomes in a patient population with a historically high mortality rate. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT04530604; URL: www. CLINICALTRIALS: gov.
引用
- Frame D, Scappaticci GB, Braun TM, et al. Defibrotide Therapy for SARS-CoV-2 ARDS. Chest. 2022. PMID: 35413279. doi:10.1016/j.chest.2022.03.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。